Immatics Initiates Phase 1/2 Clinical Trial to Evaluate PRAME TCR Bispecific IMA402 in Patients with Advanced Solid Tumors
TCER® IMA402 is the first next-generation, half-life extended TCR Bispecific targeting PRAME to enter the clinic Patient…
TCER® IMA402 is the first next-generation, half-life extended TCR Bispecific targeting PRAME to enter the clinic Patient…
Immatics’ second TCR Bispecifics program IMA402 demonstrates tumor cell killing in vitro and complete regressions of…
Immatics’ first TCR Bispecific program IMA401 delivers preclinical proof-of-concept demonstrating complete remissions of…
GSK to obtain access to two Immatics TCR-T programs, further advancing their commitment to the field of cell therapies I…
Immatics today announced a collaboration with Roche to evaluate the safety and efficacy of IMA101, Immatics' investigati…
- Immatics and Genmab to Combine Proprietary Technologies to Create Transformative Bispecific Therapies against Novel, P…
Immatics, a leading company in the field of cancer immunotherapy, announced today that Roche has exercised its option un…
Amgen (NASDAQ:AMGN) and Immatics Biotechnologies GmbH, a leading company in the field of cancer immunotherapy, today…